All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
The Lymphoma Hub was pleased to speak to Elizabeth Budde, City of Hope Comprehensive Cancer Center, Duarte, US. We asked about the long-term outcomes of fixed-duration mosunetuzumab in B-cell non-Hodgkin lymphoma (B-NHL).
What were the long-term outcomes of fixed-duration mosunetuzumab in B-NHL?
In this interview, Dr Budde discusses the long-term outcomes of treatment with fixed-duration mosunetuzumab in patients with B-NHL, with a focus on follicular lymphoma. Budde reviews the efficacy and safety data from the extended follow-up of the phase II GO29781 (NCT02500407) dose-escalation study, addressing duration of response, remission, overall survival (OS), and CD19-positive B-cell recovery. Budde also describes the characteristics of mosunetuzumab, including its outpatient administration and minimal steroid use.
*Data submitted for publication.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox